Company Encyclopedia
View More
name
BOJI CRO
300404.SZ
Boji Medical Technology Co.,Ltd. provides professional contract research services for research and development, and production of drugs and medical devices to pharmaceutical enterprises in China and internationally. It offers pre-clinical research, clinical research, and other consulting services. The company also provides clinical drug production, pilot test scale-up, process verification batch production, and drug registration and approval services.
550.52 B
300404.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Life Sciences Tools and ServicesIndustry
Industry Ranking19/27
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE0.74%D
    • Profit Margin0.96%C
    • Gross Margin25.89%C
  • Growth ScoreC
    • Revenue YoY2.26%C
    • Net Profit YoY-83.38%E
    • Total Assets YoY7.06%B
    • Net Assets YoY4.22%C
  • Cash ScoreB
    • Cash Flow Margin10389.75%A
    • OCF YoY2.26%C
  • Operating ScoreC
    • Turnover0.5C
  • Debt ScoreB
    • Gearing Ratio33.62%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    BOJI CRO released its performance for the first three quarters, with a net profit attributable to the parent company of 21.9139 million yuan, a decrease of 49.36%

    BOJI CRO released its Q3 2025 report, with operating revenue for the first three quarters at 584 million yuan, a year-on-year increase of 5.06%. The net profit attributable to the parent company was 21.9139 million yuan, a year-on-year decrease of 49.36%; the net profit after deducting non-recurring gains and losses was 14.9812 million yuan, a year-on-year decrease of 57.06%. The basic earnings per share were 0.0571 yuan

    Zhitong·
    SZ
    300404
    +0.73%
    Zhitong·
    SZ
    300404
    +0.73%

    BOJI CRO: Subsidiary Guangzhou Huasheng Pharmaceutical has obtained a drug registration certificate

    BOJI CRO's subsidiary, Guangzhou Huasheng Pharmaceutical Co., Ltd., has obtained the "Drug Registration Certificate" issued by the National Medical Products Administration, approving its production of "Compound Polyethylene Glycol Electrolyte Powder." This drug is used for bowel cleansing prior to endoscopic or radiographic examinations and colon surgeries, with an expected sales scale of approximately RMB 220 million in public hospitals in China in 2024

    Zhitong·
    SZ
    300404
    +0.73%
    Zhitong·
    SZ
    300404
    +0.73%

    Xiao Fang Pharma entrusts BOJI CRO to develop traditional Chinese medicine Class 1 new drug "Compound Arborvitae Tincture" (indication for hair loss)

    Xiao Fang Pharma and BOJI CRO signed a technical entrustment contract, in which BOJI CRO will assist in completing the clinical research and registration of the traditional Chinese medicine Class 1 new drug "Compound Arborvitae Tincture." This cooperation marks an important progress for Xiao Fang Pharma in the field of innovative drugs, as both parties will leverage their respective advantages to enhance R&D efficiency and lay the foundation for product launch

    Zhitong·
    SH
    603207
    +0.62%
    SZ
    300404
    +0.73%
    Zhitong·
    SH
    603207
    +0.62%
    SZ
    300404
    +0.73%

    BOJI CRO obtained an invention patent for the "Method for Determining Gallic Acid in Berberine."

    BOJI CRO recently obtained an invention patent issued by the National Intellectual Property Administration, with the patent name "A Method for Determining Gallic Acid in Berberine," certificate number 8272934, patent number ZL202510318197.1. This method has good separation effects in the field of drug component detection, with a short detection time and high resolution. Although it has little impact on the company's operating performance, it helps with technological innovation and enhances core competitiveness

    Zhitong·
    SZ
    300404
    +0.73%
    Zhitong·
    SZ
    300404
    +0.73%

    BOJI CRO: "FCZR" has received the drug clinical trial approval notice

    BOJI CRO recently announced that its application for "FCZR" has received the clinical trial approval notice from the National Medical Products Administration. FCZR is a modified new drug targeting ear fungal disease, with significant clinical advantages. The drug's formulation and administration method have been optimized for ear drop application, allowing it to directly act on the ear canal lesions. Currently, there are no similar drugs approved for marketing domestically or internationally

    Zhitong·
    SZ
    300404
    +0.73%
    Zhitong·
    SZ
    300404
    +0.73%
    © 2025 Longbridge｜Disclaimer